# US 2004/0018252 A1 · Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018252 A1
- Document ID: US20040018252A1
- Status: Published application
- Kind: A1
- Application number: 10/447,333
- Filed: 2003-05-28
- Published: 2004-01-29
- Earliest claimed: 2000-09-20
- Inventors: Lee Shahinian JR.
- Web page: https://patentgrep.com/patent/US20040018252A1

## CPC

- A61K 9/0043: {Nose}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Self-preserved nasal, inhalable and topical ophthalmic preparations and medications which destroy, inhibit or therapeutically significantly limit microbial growth within said preparations or medications. The nasal, inhalable, and topical ophthalmic preparations and medications are mildly buffered and maintain a stable pH at pH 3.5 or lower.

## Claims

### Claim 1

A self-preserved preservative-free topical ophthalmic, inhalable or nasal formulation comprising:
a pharmaceutically acceptable excipient or additive selected from the group consisting of a pharmaceutically acceptable excipient or additive selected from the group consisting of dextrose, polyethylene glycol (PEG), hydroxypropyl methylcellulose (HPMC), sodium chloride, potassium chloride, calcium chloride, magnesium chloride, phosphoric acid, disodium edetate, bicarbonate, phosphate, povidone, carboxymethylcellulose, hydroxyethylcellulose, methylcellulose, microcrystalline cellulose, other cellulose derivatives, glycerin, polyvinyl alcohol, dextran 40, dextran 70, mannitol, gelatin, polyols, polysorbate 80, propylene glycol, zinc sulfate, poloxamer 188, 282, 407, ephedrine hydrochloride, naphazoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, lecithin, oleic acid and sorbitan, pheniramine maleate, pyrilamine maleate, antazoline phosphate, glycine, camphor, eucalyptol, menthol, benzyl alcohol, lavender oil, tyloxapol, bornyl acetate, and phenylethyl alcohol, alone or in admixture; and
a buffering agent;
said formulation adjusted to pH from about pH 1.5 to pH about 3.5.

### Claim 2 (depends on 1)

The formulation of claim 1 wherein pH is adjusted to pH from about pH 2.0 to about 2.5.

### Claim 3 (depends on 2)

The formulation of claim 2 wherein the pH is about 2.5.

### Claim 4 (depends on 3)

The formulation of claim 3 wherein the buffering agent is acetic, citric, formic, glutaric, glycolic, lactic, maleic or tartaric acid or a salt thereof.

### Claim 5 (depends on 4)

The formulation of claim 4 wherein the buffering agent is citric acid.

### Claim 6 (depends on 5)

The formulation of claim 5 wherein the excipient, additive or a pharmaceutical agent is present in amount from 0.001 to about 8% and wherein the buffering agent is present in amount from about 0.001 to about 0.02%.

### Claim 7 (depends on 6)

The formulation of claim 6 comprising about 1-8% of polyethylene glycol, about 0.1% to about 0.3% of hydroxypropyl methylcellulose, about 0.01% to about 0.02% citric acid and purified water, wherein the pH is adjusted to about pH 2.5.

### Claim 8 (depends on 7)

The formulation of claim 7 comprising about 8% of polyethylene glycol, about 0.3% of hydroxypropyl methylcellulose, about 0.01% citric acid and purified water, wherein the pH is adjusted to about pH 2.5.

### Claim 9 (depends on 8)

The formulation of claim 8 wherein the pH is adjusted with an acid or a base.

### Claim 10 (depends on 9)

The formulation of claim 9 wherein the acid is hydrochloric acid or sulphuric acid and wherein the base is sodium hydroxide or ammonium hydroxide.

### Claim 11 (depends on 7)

The formulation of claim 7 additionally comprising about 2 to 6% of dextrose.

### Claim 12 (depends on 11)

The formulation of claim 11 comprising about 4% of dextrose, about 1% of polyethylene glycol, about 0.3% of hydroxypropyl methylcellulose and about 0.01% of citric acid.

### Claim 13 (depends on 12)

The formulation of claim 12 wherein the pH is adjusted with an acid or a base.

### Claim 14 (depends on 9)

The formulation of claim 9 wherein the acid is hydrochloric acid, phosphoric acid or sulphuric acid and wherein the base is sodium hydroxide or ammonium hydroxide.

### Claim 15

A method for preparation of a topical ophthalmic, nasal or inhalable self-preserved solution comprising steps of:
a) preparing a formulation comprising
a pharmaceutically acceptable excipient or additive selected from the group consisting of dextrose, polyethylene glycol (PEG), hydroxypropyl methylcellulose (HPMC), sodium chloride, potassium chloride, calcium chloride, magnesium chloride, phosphoric acid, disodium edetate, bicarbonate, phosphate, povidone, carboxymethylcellulose, hydroxyethylcellulose, methylcellulose, microcrystalline cellulose, other cellulose derivatives, glycerin, polyvinyl alcohol, dextran 40, dextran 70, mannitol, gelatin, polyols, polysorbate 80, propylene glycol, zinc sulfate, poloxamer 188, 282, 407, ephedrine hydrochloride, naphazoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, lecithin, oleic acid and sorbitan, pheniramine maleate, pyrilamine maleate, antazoline phosphate, glycine, camphor, eucalyptol, menthol, benzyl alcohol, lavender oil, tyloxapol, bornyl acetate, and phenylethyl alcohol, alone or in admixture; and
a buffering agent; and
b) adjusting pH of said formulation to from about pH 1.5 to pH about 3.5.

### Claim 16 (depends on 15)

The method of claim 15, wherein the buffering agent is citric acid or sodium citrate and wherein the pH is adjusted to pH about 2.0 to about 2.5.

### Claim 17 (depends on 16)

The method of claim 16, wherein the pH is adjusted to pH about 2.5.

### Claim 18 (depends on 17)

The method of claim 17, wherein the solution is used as a topical eye preparation for administration of a pharmaceutical agent, artificial tear, contact lens solution or eye irrigating solution.

### Claim 19 (depends on 18)

The method of claim 18, the pharmaceutical agent is selected from the group consisting of an analgesic, anti-inflammatory, astringent, antihistamine, mast cell stabilizer, diagnostic aid, fluorescein, miotic, mydriatic, antibiotic, antiviral, antifungal, vasoconstricting agent, antiglaucoma medication, hypertonicity agent, decongestant, bronchodilator and topical anesthetic, said pharmaceutical agent present in from about 0.001 to about 8%.

### Claim 20 (depends on 19)

The method of claim 19 wherein the anesthetic is proparacaine, tetracaine, lidocaine, benoxinate, and bupivicaine.
